0 12 Epstein-Barr epstein-barr JJ 13 31 virus-transforming virus-transforming JJ 32 39 protein protein NN 40 46 latent latent JJ 47 56 infection infection NN 57 65 membrane membrane NN 66 73 protein protein NN 74 75 1 1 CD 76 85 activates activate VBZ 86 99 transcription transcription NN 100 106 factor factor NN 107 116 NF-kappaB nf-kappab NN 117 124 through through IN 125 126 a a DT 127 134 pathway pathway NN 135 139 that that WDT 140 148 includes include VBZ 149 152 the the DT 153 171 NF-kappaB-inducing NF-kappaB-inducing NNP 172 178 kinase kinase NNP 179 182 and and CC 183 186 the the DT 187 194 IkappaB IkappaB NNP 195 202 kinases kinase NNS 203 211 IKKalpha IKKalpha NNP 212 215 and and CC 216 223 IKKbeta IKKbeta NNP 223 224 . . . 226 229 The the DT 230 242 Epstein-Barr epstein-barr JJ 243 248 virus virus NN 249 260 oncoprotein oncoprotein NN 261 267 latent latent JJ 268 277 infection infection NN 278 286 membrane membrane NN 287 294 protein protein NN 295 296 1 1 CD 297 298 ( ( ( 298 302 LMP1 lmp1 NN 302 303 ) ) ) 304 306 is be VBZ 307 308 a a DT 309 323 constitutively constitutively RB 324 334 aggregated aggregate VBN 335 347 pseudo-tumor pseudo-tumor NN 348 356 necrosis necrosis NN 357 363 factor factor NN 364 372 receptor receptor NN 373 374 ( ( ( 374 378 TNFR TNFR NNP 378 379 ) ) ) 380 384 that that WDT 385 394 activates activate VBZ 395 408 transcription transcription NN 409 415 factor factor NN 416 425 NF-kappaB nf-kappab NN 426 433 through through IN 434 437 two two CD 438 443 sites site NNS 444 446 in in IN 447 450 its its PRP$ 451 461 C-terminal c-terminal JJ 462 473 cytoplasmic cytoplasmic JJ 474 480 domain domain NN 480 481 . . . 482 485 One one CD 486 490 site site NN 491 493 is be VBZ 494 501 similar similar JJ 502 504 to to TO 505 514 activated activate VBN 515 521 TNFRII TNFRII NNP 522 524 in in IN 525 536 associating associate VBG 537 541 with with IN 542 557 TNFR-associated tnfr-associated JJ 558 565 factors factor NNS 566 571 TRAF1 TRAF1 NNP 572 575 and and CC 576 581 TRAF2 TRAF2 NNP 581 582 , , , 583 586 and and CC 587 590 the the DT 591 597 second second JJ 598 602 site site NN 603 605 is be VBZ 606 613 similar similar JJ 614 616 to to TO 617 622 TNFRI TNFRI NNP 623 625 in in IN 626 637 associating associate VBG 638 642 with with IN 643 646 the the DT 647 652 TNFRI TNFRI NNP 653 658 death death NN 659 665 domain domain NN 666 677 interacting interact VBG 678 685 protein protein NN 686 691 TRADD TRADD NNP 691 692 . . . 693 698 TNFRI TNFRI NNP 699 702 has have VBZ 703 707 been be VBN 708 716 recently recently RB 717 722 shown show VBN 723 725 to to TO 726 734 activate activate VB 735 744 NF-kappaB NF-kappaB NNP 745 752 through through IN 753 764 association association NN 765 769 with with IN 770 775 TRADD TRADD NNP 775 776 , , , 777 780 RIP RIP NNP 780 781 , , , 782 785 and and CC 786 791 TRAF2 traf2 NN 791 792 ; ; : 793 803 activation activation NN 804 806 of of IN 807 810 the the DT 811 829 NF-kappaB-inducing NF-kappaB-inducing NNP 830 836 kinase kinase NNP 837 838 ( ( ( 838 841 NIK NIK NNP 841 842 ) ) ) 842 843 ; ; : 844 854 activation activation NN 855 857 of of IN 858 861 the the DT 862 869 IkappaB IkappaB NNP 870 875 alpha alpha NN 876 883 kinases kinase NNS 884 885 ( ( ( 885 893 IKKalpha IKKalpha NNP 894 897 and and CC 898 905 IKKbeta IKKbeta NNP 905 906 ) ) ) 906 907 ; ; : 908 911 and and CC 912 927 phosphorylation phosphorylation NN 928 930 of of IN 931 938 IkappaB IkappaB NNP 939 944 alpha alpha NN 944 945 . . . 946 953 IkappaB IkappaB NNP 954 959 alpha alpha NN 960 975 phosphorylation phosphorylation NN 976 978 on on IN 979 985 Ser-32 Ser-32 NNP 986 989 and and CC 990 996 Ser-36 Ser-36 NNP 997 999 is be VBZ 1000 1008 followed follow VBN 1009 1011 by by IN 1012 1015 its its PRP$ 1016 1027 degradation degradation NN 1028 1031 and and CC 1032 1041 NF-kappaB nf-kappab NN 1042 1052 activation activation NN 1052 1053 . . . 1054 1056 In in IN 1057 1061 this this DT 1062 1068 report report NN 1068 1069 , , , 1070 1072 we we PRP 1073 1077 show show VBP 1078 1082 that that IN 1083 1092 NF-kappaB NF-kappaB NNP 1093 1103 activation activation NN 1104 1106 by by IN 1107 1111 LMP1 LMP1 NNP 1112 1114 or or CC 1115 1117 by by IN 1118 1122 each each DT 1123 1125 of of IN 1126 1129 its its PRP$ 1130 1138 effector effector NN 1139 1144 sites site NNS 1145 1147 is be VBZ 1148 1156 mediated mediate VBN 1157 1159 by by IN 1160 1161 a a DT 1162 1169 pathway pathway NN 1170 1174 that that WDT 1175 1183 includes include VBZ 1184 1187 NIK NIK NNP 1187 1188 , , , 1189 1197 IKKalpha IKKalpha NNP 1197 1198 , , , 1199 1202 and and CC 1203 1210 IKKbeta IKKbeta NNP 1210 1211 . . . 1212 1220 Dominant dominant JJ 1221 1229 negative negative JJ 1230 1237 mutants mutant NNS 1238 1240 of of IN 1241 1244 NIK NIK NNP 1244 1245 , , , 1246 1254 IKKalpha IKKalpha NNP 1254 1255 , , , 1256 1258 or or CC 1259 1266 IKKbeta IKKbeta NNP 1267 1280 substantially substantially RB 1281 1290 inhibited inhibit VBD 1291 1300 NF-kappaB NF-kappaB NNP 1301 1311 activation activation NN 1312 1314 by by IN 1315 1319 LMP1 LMP1 NNP 1320 1322 or or CC 1323 1325 by by IN 1326 1330 each each DT 1331 1333 of of IN 1334 1337 its its PRP$ 1338 1346 effector effector NN 1347 1352 sites site NNS 1352 1353 . . .